Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053323 | 0.94 | ALDH1A1 (0.53) | EEF2KMAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4050143 | 0.91 | MAPT (0.47) | EEF2KMAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4050745 | 0.91 | MAPT (0.46) | EEF2KMAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4054586 | 0.89 | TRPM8 (0.50) | MAPTALDH1A1SMN1; SMN2L3MBTL1NPSR1 | |
| SCHEMBL4054042 | 0.89 | MAPT (0.43) | EEF2KMAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4055756 | 0.89 | MAPT (0.45) | EEF2KMAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4052538 | 0.87 | MAPT (0.43) | EEF2KMAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4048435 | 0.87 | MAPT (0.41) | EEF2KMAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4055124 | 0.85 | EEF2K (0.52) | EEF2KALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL4048954 | 0.82 | MAPT (0.51) | MAPTALDH1A1SMN1; SMN2L3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | EEF2K 3502/4885MAPT 4415/4885ALDH1A1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.